YusufMendaMD

Nuclear Medicine • Iowa City, IA

Associate Professor, Radiology, University of Iowa College of Medicine

Join to view full profile

Dr. Menda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Menda's full profile

Already have an account?

Office
200 Hawkins Dr
Iowa City, IA 52242
Phone+1 319-356-3214

Fax+1 319-356-2220
Is this information wrong?

Education & Training

University of Iowa Hospitals and ClinicsResidency, Nuclear Medicine, 1998 - 2000
Istanbul University FomClass of 1994

Certifications & Licensure

IA State Medical License 1998 - 2026
American Board of Nuclear Medicine Nuclear Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer Start of enrollment: 2005 Oct 01
Completed
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Start of enrollment: 2008 Mar 01
Completed
Phase 2
Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer Start of enrollment: 2009 Jul 01
Withdrawn
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Start of enrollment: 2012 Oct 01
Completed
Phase 2
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors Start of enrollment: 2017 Nov 03
Active, not recruiting
Early Phase 1
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Start of enrollment: 2022 Sep 30
Withdrawn
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

46 citations
Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi para...
Damita Thomas, Twyla Bartel, Yusuf Menda, James R. Howe, Michael M. Graham
Clinical Nuclear Medicine. 2009-10-01
91 citations
Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancer—A Long-Term Outcome Report
Min Yao, Russell B. Smith, Henry T. Hoffman, Gerry F. Funk, Minggen Lu
International Journal of Radiation Oncology, Biology, Physics. 2009-05-01
73 citations
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Thomas A. Hope, Lisa Bodei, Jennifer A. Chan, Ghassan El-Haddad, Nicholas Fidelman
Journal of Nuclear Medicine. 2020-02-01

Press Mentions

A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy (RPT): An ASTRO Consensus DocumentNovember 26th, 2020
UI Neuroendocrine Tumor Program Earns High European DistinctionMarch 11th, 2019
UI Neuroendocrine Tumor Program Earns High European DistinctionMarch 11th, 2019
Join now to see all

Hospital Affiliations

University of Iowa Hospitals and ClinicsIowa City, Iowa